Fortrea Holdings Inc. — FY2023 Form 10-K
Business context and reporting period. Fortrea is a global contract research organization providing clinical development, clinical pharmacology, patient access and trial technology services. This annual report covers the year ended December 31, 2023; it does not provide a clear standalone fourth-quarter income statement. Fortrea completed its spin-off from Labcorp on June 30, 2023 and began trading independently on July 3. Pre-spin results are carve-out financials and may not reflect standalone costs or performance.
Key financial metrics
Amounts are in millions of dollars unless noted.
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $3,109.0 | $3,096.1 |
| Operating income | $63.1 | $235.9 |
| Net income (loss) | $(3.4) | $192.9 |
| Operating cash flow | $167.4 | $87.5 |
| Capital expenditures | $40.3 | $54.4 |
| Cash and cash equivalents, year-end | $108.6 | $112.0 |
| Debt principal, year-end | $1,624.7 | No debt shown |
- Revenue increased 0.4% year over year, comprising 0.3% organic growth and 0.1% favorable currency translation. Direct costs were 83.3% of revenue versus 79.0%; SG&A was 10.8% versus 9.0%.
- Operating margin was approximately 2.0%, down from 7.6%; net margin was approximately (0.1)%, versus 6.2%. Interest expense rose to $69.8 from $0.2 following spin-related borrowing. Income tax expense was $4.5 on pretax income of $1.1, an effective rate of 406.3%.
- Clinical Services revenue was $2,839.5, up 0.5%; segment operating income was $243.0, down 41.2%. Enabling Services revenue was $269.5, down 0.4%; segment operating income was $11.4, down 53.3%. Segment operating income excludes corporate costs and other unallocated items.
- Cash from operations improved by $79.9 year over year. Net cash declined $3.4, with investing outflows of $31.8 and financing outflows of $139.0. The company reported $348.4 available on its $450 million revolving facility and no year-end balance on that facility.
- Year-end current assets were $1,253.1 and current liabilities $775.9. Accounts receivable and unbilled services, net, were $1,052.1, including a $32.3 credit-loss allowance, up from $12.7.
Material changes versus the prior comparable period
- Revenue was nearly flat, while operating income fell 73.3% and the company moved from profit to a small net loss. Higher personnel, pass-through and transition-services costs, increased credit-loss provisions, and lower service revenue contributed to pressure.
- Debt increased substantially in connection with the spin: $570 million of 7.5% senior notes and term loans. Term-loan effective rates at year-end were 7.61% and 9.11%; the company reported compliance with debt covenants.
- Operating cash flow rose from $87.5 to $167.4, while capital expenditures declined from $54.4 to $40.3.
Outlook, commentary, risks and unusual items
- Management said existing cash, operating cash flow and credit facilities should be sufficient for current and planned operations for at least 12 months. No company-specific revenue or earnings guidance is provided. The filing cites industry estimates of CRO-market growth of approximately 3–5% over the next two years and 6–9% longer term; these are industry expectations, not Fortrea guidance.
- Backlog was $7.4 billion at year-end, but the company cautions it is not a consistent predictor of future revenue because awards may be delayed, canceled, reduced or fail to reach contract. Unsatisfied performance obligations under long-term contracts were $4,762.8; about 31% was expected to be recognized over the following 12 months.
- On March 9, 2024, Fortrea agreed to sell Patient Access and Endpoint Clinical assets for $345 million, subject to adjustments: $295 million payable at closing and $50 million tied to transition milestones. Closing was targeted for Q2 2024, subject to conditions and approvals.
- A third-party vendor’s dosing-sequence errors in a customer trial led Fortrea to agree to an estimated $12.5 million in concessions and other consideration; $5.5 million was recorded as a 2023 revenue reduction. Restructuring charges were $24.3, and restructuring actions were expected to continue through 2024.
- Key risks include customer award delays or cancellations, customer and therapeutic-area concentration, patient and investigator recruitment, cost overruns, credit collection, reliance on third parties and Labcorp transition services, cybersecurity and privacy compliance, regulation, foreign exchange, and leverage. One customer contributed 10.6% of 2023 revenue; the top ten contributed approximately 47%.
- The independent auditor gave an unmodified opinion on the financial statements. The company was not required to provide an auditor opinion on internal control over financial reporting for this filing; management reported disclosure controls were effective. The filing notes no material cybersecurity incident known to the company.
Important facts for investors to verify
- Whether service revenue, new awards and backlog conversion improve, and how cancellations or delays affect revenue and margins.
- Whether higher credit-loss provisions and the large receivables and unbilled-services balance result in timely collections and sustained operating cash flow.
- Debt-service capacity, variable-rate exposure, covenant headroom and refinancing needs; the filing estimates a 1 percentage-point rate increase would add about $10.5 of annual interest expense before swaps.
- Completion, proceeds and transition costs of the planned $345 million Enabling Services divestiture, including the milestone-dependent payment.
- Standalone operating costs and the timely exit from Labcorp transition arrangements, plus the outcome of the customer concessions related to the trial dosing errors.